ASTERASYS Co., Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name ASTERASYS Co., Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 11.7%
- Equity ratio
- 89.6%
- ROE
- 19.7%
- Op. margin
- 27.4%
- Rev. growth
- 31.6%
- Interest coverage
- n/a
Condition flags
- Operating profit for 2 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩105 | 43.1% |
| 2024 | ₩32 | 19.6% |
| 2023 | n/a | n/a |
Cash dividends for 2 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 171.4% | 36.9% | 64.6% | 21.2% | n/a |
| FY2024 consolidated | 25.9% | 79.4% | 27.3% | 23.1% | n/a |
| FY2025 consolidated | 11.7% | 89.6% | 19.7% | 27.4% | 31.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2024 | 2025 |
|---|---|---|---|
| Revenue | ₩14.4B | ₩28.8B | ₩37.9B |
| Operating profit | ₩3.1B | ₩6.7B | ₩10.4B |
| Pre-tax income | ₩2.5B | ₩6.3B | ₩10.8B |
| Net income | ₩2.5B | ₩5.4B | ₩9.2B |
| Total assets | ₩10.5B | ₩24.7B | ₩52.2B |
| Total liabilities | ₩6.6B | ₩5.1B | ₩5.4B |
| Total equity | ₩3.9B | ₩19.6B | ₩46.8B |
| Paid-in capital | ₩3.0B | ₩3.3B | ₩3.8B |
| Debt/equity (source value) | 171.4% | 25.9% | 11.7% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2015-07-07
- Listed
- 25/01/24
- Employees
- 88
- Auditor
- 이촌회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1412110077086
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 아스테라시스Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.